Biogen Idec Inc. (BIIB) was a big mover last session with shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company …
Analysts are optimistic about the quarter. Credit Suisse's Alethia Young reiterated a Neutral rating Amgen, but she has a $194 price target, comfortably above the …
(Reuters) - Biogen Inc's second-quarter profit smashed estimates on Tuesday, boosted by strong sales of its spinal muscular atrophy (SMA) drug, Spinraza, which is priced at $750,000 for the first year of therapy. Buoyed by the …
Jan 25 (Reuters) - Biogen Inc ::BIOGEN REPORTS RECORD REVENUES FOR BOTH THE FULL YEAR AND FOURTH QUARTER OF 2017, $12.3 BILLION AND $3.3 BILLION, RESPECTIVELY.2018 FULL YEAR REVENUE GUIDANCE …
Feb 28 (Reuters) - Nestle SA-backed Accera Inc said on Tuesday its experimental Alzheimer's drug failed a late-stage study, adding to the laundry list of disappointments in the pursuit of an effective treatment for the rampant mind-wasting …
Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global …